Adma Biologics Inc   (ADMA)
Other Ticker:  
Price: $3.7300 $0.01 0.269%
Day's High: $3.85 Week Perf: -5.57 %
Day's Low: $ 3.72 30 Day Perf: 13.03 %
Volume (M): 1,583 52 Wk High: $ 4.65
Volume (M$): $ 5,906 52 Wk Avg: $3.64
Open: $3.73 52 Wk Low: $2.95

 Market Capitalization (Millions $) 872
 Shares Outstanding (Millions) 234
 Employees 256
 Revenues (TTM) (Millions $) 233
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) 39
 Capital Exp. (TTM) (Millions $) 7

Adma Biologics Inc
Adma Biologics Inc.
is a publicly traded biopharmaceutical company based in New Jersey, United States.
It is primarily focused on the development and commercialization of plasma-based biologics for the treatment of a variety of infectious diseases and disorders.
Adma Biologics was founded in 2004 and has since then become a leader in the plasma-derived therapeutics field.
The company has developed and marketed a number of FDA-approved intravenous immunoglobulin (IVIG) products for the treatment of primary humoral immunodeficiency disease.
IVIG products manufactured by Adma Biologics are derived from human plasma collected from a variety of qualified sources in the US, and are purified and treated to remove any viral, bacterial, or other contaminants that could compromise the product's safety and efficacy.
In addition to IVIG products, Adma Biologics has also developed Bivigam' and Nabi-HB' for the treatment of Hepatitis B and C in specific patient populations.
The company is also developing products for the treatment of pneumococcal and other bacterial infections.
The company's proprietary technology, called RI-002, enables the production of highly concentrated, pure polyclonal human immunoglobulin G (IgG) for the treatment and prevention of a wide range of viral and bacterial infections.
The technology has the potential to revolutionize the production of high-quality, pure biologic products that are safe and effective for human use.
Overall, Adma Biologics is dedicated to improving the lives of patients with serious and life-threatening medical conditions by developing innovative therapies that address unmet medical needs.
The company's research and development efforts are focused on creating new treatments for infectious diseases, autoimmune disorders, and other serious medical conditions, with the goal of providing safe and effective therapies that can improve the overall quality of life for patients.

   Company Address: 465 State Route 17 Ramsey 7446 NJ
   Company Phone Number: 478-5552   Stock Exchange / Ticker: NASDAQ ADMA
   ADMA is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Semper Paratus Acquisition Corporation

The arising business from the Biotechnology and Pharmaceuticals market the LGST published the fiscal third quarter of 2023, numbers

The Biotechnology and Pharmaceuticals sector experts continue to interpret the third quarter of 2023 earnings. Presently those experts observe operating deficit of $-0.605971 million, from the Semper Paratus Acquisition Corporation, which has not cited any top-line so far, for the own July to September 30 2023 quarter.

Ladrx Corporation

Ladrx Corporation's Fiscal Report Reveals Operating Shortfall of $-0.840313 Million in Biotechnology and Pharmaceuticals Sector for September 2023

The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology and Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.

Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc's Trailblazing Journey: Overcoming a Surprising $-0.04 per Share Loss Amidst the Fiscal Time-frame Ending September 30, 2023

For the fiscal time-frame ending September 30 2023 LCTX lost money of $-0.04 per share compare to $-0.04 a year before and surged loss from $-0.03 per share from the previous quarter. The revenue fell sharply by -58.439 % to $1.25 million from $3.00 million in the comparable quarter a year before and sequentially Revenue Tumbled by -61.364 % from $3.23 million.

Bio Techne Corp

Reduction in Earnings while revenue grew in the July to September 30 2023 fiscal time-frame

Revenue improvement of 2.447 %, could not prevent income decline of -85.97 % in the most recent fiscal period, relative to comparable reporting period a year before. revenue were at $276.19 million and eps at $0.31.

Anavex Life Sciences Corp

Anavex Life Sciences Corp's EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023

Date: November 30, 2023
Anavex Life Sciences Corp, a renowned Biotechnology and Pharmaceuticals company, recently reported its financial results for the fiscal fourth quarter of 2023. Despite a sharp decline in revenue, the company's earnings per share (EPS) witnessed a commendable surge. Let's delve into the details of these results and analyze what this means for the future of the company.
In the fiscal fourth quarter of 2023, Anavex Life Sciences Corp reported a staggering EPS growth of 454.76%. The EPS rose to $0.48 per share, compared to $0.09 per share in the same quarter a year ago. Moreover, the company was able to turn its EPS positive, bouncing back from a loss of $-0.14 per share in the prior quarter. This robust growth in earnings is undoubtedly a positive sign for shareholders and investors.


Adma Biologics Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com